FDA Accepts Cogent’s NDA for Bezuclastinib in Advanced Systemic Mastocytosis
Event summary
- FDA accepted Cogent’s NDA for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) with a PDUFA target action date of June 29, 2027.
- The NDA is supported by positive results from the APEX pivotal trial, showing a 65% overall response rate and 81% response by pure pathological response (PPR) criteria.
- Cogent also has NDAs under review for NonAdvanced Systemic Mastocytosis (PDUFA date: December 30, 2026) and GIST (PDUFA date: November 30, 2026).
- The company established Expanded Access Programs (EAPs) for U.S. patients with SM or GIST.
- Cogent granted inducement equity awards to nine new employees under its 2020 Inducement Plan.
The big picture
Cogent’s NDA acceptance for bezuclastinib in AdvSM marks a critical step in its strategy to target KIT-driven diseases. The company is positioning itself as a leader in precision therapies for genetically defined diseases, with multiple regulatory milestones on the horizon. The acceptance reinforces the potential of bezuclastinib across a broad spectrum of indications, setting the stage for potential commercial launches and expanded market reach.
What we're watching
- Regulatory Timing
- Whether the FDA will meet the PDUFA target action dates for bezuclastinib across all three indications.
- Commercial Readiness
- How Cogent’s commercial and medical teams prepare for potential launches later this year.
- Clinical Efficacy
- The durability of bezuclastinib’s clinical activity in AdvSM patients as more data matures.
Related topics